Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis
Sarah Dewilde, Alison Griffiths, Cynthia Z. Qi, Glenn Phillips, Deborah Gelinas, Edward Brauer, Renato Mantegazza, James F. Howard
Topics & Concepts
Myasthenia gravisPost hocPost-hoc analysisMedicineAggregate (composite)Physical medicine and rehabilitationPsychologyInternal medicineMaterials scienceNanotechnologyMyasthenia Gravis and ThymomaAdrenal Hormones and DisordersPeripheral Neuropathies and Disorders